Candel Therapeutics raises $15M via registered direct offering of 3.2M shares at $4.67

Candel Therapeutics, Inc.

Gross proceeds ~$15M from sale of 3,221,395 shares at $4.67/share; closing expected June 25, 2025.
Purchasers include existing healthcare-focused institutional investors, executive officers, and directors.
Net proceeds to support pre-commercialization and launch readiness for CAN-2409 in prostate cancer; BLA submission planned Q4 2026.
Insider participation signals confidence in Candel's strategy and pipeline.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.